Jumia Technologies AG
Change company Symbol lookup
Select an option...
JMIA Jumia Technologies AG
BVH Bluegreen Vacations Holding Corp
GTY Getty Realty Corp
SWX Southwest Gas Holdings Inc
EFR Eaton Vance Senior Floating-Rate Trust
FSRXW FinServ Acquisition II Equity Warrant Exp 17 Feb 2026 *W EXP 02/17/2026
PTRA Proterra Inc
IH Ihuman Inc
LMT Lockheed Martin Corp
GBRGU Goldenbridge Acquisition Ltd

Consumer Discretionary : Internet & Direct Marketing Retail |
Based in Germany
Company profile

Jumia Technologies AG is a Germany-based e-commerce platform provider. The Company’s platform consist of sellers with consumers, its logistics service, which enables the shipment and delivery of packages from sellers to consumers, and its payment service, which facilitates transactions among participants active on the Company’s platform. The Company’s marketplace is consists of a range of sellers that offer goods in a wide range of categories, such as fashion and apparel, smartphones, home and living, consumer packaged goods, beauty and perfumes and other electronics. The Company also provide consumers with access to a various services, such as restaurant food delivery, hotel and flight booking, classified advertising and airtime recharge.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
2.08 (18.78%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 6,345,022 shares is on pace to be much greater than JMIA's 10-day average volume of 5,155,949 shares.


Moderna says its COVID-19 shot generates 'robust' response in children 6 to 11

8:52 am ET October 25, 2021 (MarketWatch)

Shares of Moderna Inc. (MRNA) gained 0.9% in premarket trading on Monday after the company shared interim data from a Phase 2/3 clinical study evaluating its COVID-19 vaccine in children between the ages of 6 and 11 years old. The trial, which has 4,753 participants between the ages of 6 and 11, evaluated the immune response one month after the second dose. Moderna said the vaccine met the trial's endpoint and generated a "robust neutralizing antibody response" but it did not provide an efficacy rate in the news release. The company also said it plans to submit the clinical data to the FDA in the "near term." The news was announced one day before a Food and Drug Administration advisory committee is set to discuss the benefits and risks of BioNTech SE (BNTX) and Pfizer Inc.'s (PFE) COVID-19 vaccine in children between the ages of 5 and 11. The Moderna and BioNTech/Pfizer COVID-19 vaccines both require two shots and use mRNA technology. Moderna's stock has soared 212.5% so far this year, while the broader S&P 500 is up 21.0%.

-Jaimy Lee


(END) Dow Jones Newswires

October 25, 2021 08:52 ET (12:52 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.